IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Core Insights - IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease using Artificial Intelligence (AI) [1][2] - Ascendiant Capital Markets has issued a coverage report indicating positive clinical data and progress in 2025/26 as strong catalysts for the stock, raising the price target to $4.75 [1] Company Overview - IGC Pharma is leveraging AI to develop treatments for Alzheimer's and metabolic disorders, with its lead asset, IGC-AD1, currently in a Phase 2 trial for agitation in Alzheimer's dementia [2] - The company's pipeline includes TGR-63, which targets amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions [2] - IGC Pharma integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting, supported by a complete patent portfolio [2]